Tag:
Reckitt Benckiser
Latest Headlines
Latest Headlines
Reckitt bid to block Suboxone copies fails
The U.K.-based company had petitioned the agency to block the copycat versions on packaging grounds.
Bristol licenses OTC brands to Reckitt for 'eye-watering' $482M
Reckitt Benckiser has nabbed Latin American rights to a basket of Bristol-Myers Squibb's ($BMY) over-the-counter products for a cool $482 million.
Is pharma ready to capitalize on vitamin market shakeup?
When Bayer agreed to buy U.S.-based vitamin-and-OTC drug maker Schiff ($SHF), the company's reasoning went something like this: Let's supplement our risky pharma business with some steady, reliable, low-risk revenue. It's less profitable and less sexy, but sometimes, less can be more.
Bayer says trumping Reckitt's $1.4B Schiff bid is too rich
If you were looking for a bidding war over Schiff Nutrition to give your Thanksgiving feast an ironic twist, you're going to be disappointed. Bayer says it's patently not interested in trumping Reckitt Benckiser's $1.4 billion offer.
Bayer's $1.2B bid for vitamin maker topped by U.K. group
The aggressive diversification campaign of Bayer CEO Marijn Dekkers has been checked, at least temporarily, by Reckitt Benckiser Group, which has moved on Schiff Nutrition International with a bid of its own.
Reckitt petitions FDA to force 'child resistant' packaging on Suboxone rivals
Reckitt Benckiser is taking another stab at rivals to its Suboxone Film product. Reckitt announced it had petitioned FDA to require rival drugmakers to package their buprenorphine drugs in child-resistant, individually packaged doses.
Reckitt to pull Suboxone tabs in favor of on-patent film version
Reckitt Benckiser plans to pull its heroin replacement tablets in the U.S., thanks to new data showing that the Suboxone pills were more likley to be swallowed accidentally by children than other formulations were. In making this voluntary sacrifice, the company puts its alternative Suboxone product--a film version that dissolves on the tongue--in line for increased sales.
Sublingual opioid addiction therapy moves closer to market
Orexo, a Swedish pharma company, has submitted to the FDA a new drug application for Zubsolv (OX219), its under-the-tongue formulation of buprenorphine and naloxone for treatment of opioid dependence. The drug uses Orexo's sublingual drug delivery technology.
U.K. man gets 18 months for scam that led to nationwide OTC recall
A U.K. man, whose effort to feed his drug habit led to a nationwide recall of a painkiller, has been given 18 months in jail.
Sabotage suspected in U.K. painkiller case
Scotland Yard is investigating whether the OTC painkiller Nurofen Plus has been targeted by a saboteur. Consumer products group Reckitt Benckiser is recalling the drug in the U.K. after some packs
